242 related articles for article (PubMed ID: 37444618)
1. Systemic Neoadjuvant and Adjuvant Therapies in the Management of Hepatocellular Carcinoma-A Narrative Review.
Chamseddine S; LaPelusa M; Kaseb AO
Cancers (Basel); 2023 Jul; 15(13):. PubMed ID: 37444618
[TBL] [Abstract][Full Text] [Related]
2. Overview of resistance to systemic therapy in patients with breast cancer.
Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
[TBL] [Abstract][Full Text] [Related]
3. Neoadjuvant and Adjuvant Systemic Therapies in Loco-Regional Treatments for Hepatocellular Carcinoma: Are We at the Dawn of a New Era?
Nevola R; Delle Femine A; Rosato V; Kondili LA; Alfano M; Mastrocinque D; Imbriani S; Perillo P; Beccia D; Villani A; Ruocco R; Criscuolo L; La Montagna M; Russo A; Marrone A; Sasso FC; Marfella R; Rinaldi L; Esposito N; Barberis G; Claar E
Cancers (Basel); 2023 May; 15(11):. PubMed ID: 37296912
[TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer - the NEONAX trial (AIO-PAK-0313), a prospective, randomized, controlled, phase II study of the AIO pancreatic cancer group.
Ettrich TJ; Berger AW; Perkhofer L; Daum S; König A; Dickhut A; Wittel U; Wille K; Geissler M; Algül H; Gallmeier E; Atzpodien J; Kornmann M; Muche R; Prasnikar N; Tannapfel A; Reinacher-Schick A; Uhl W; Seufferlein T
BMC Cancer; 2018 Dec; 18(1):1298. PubMed ID: 30594153
[TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant and adjuvant therapy for surgical resection of hepatocellular carcinoma.
Samuel M; Chow PK; Chan Shih-Yen E; Machin D; Soo KC
Cochrane Database Syst Rev; 2009 Jan; 2009(1):CD001199. PubMed ID: 19160192
[TBL] [Abstract][Full Text] [Related]
6. Perioperative Systemic Therapy vs Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Alone for Resectable Colorectal Peritoneal Metastases: A Phase 2 Randomized Clinical Trial.
Rovers KP; Bakkers C; Nienhuijs SW; Burger JWA; Creemers GM; Thijs AMJ; Brandt-Kerkhof ARM; Madsen EVE; van Meerten E; Tuynman JB; Kusters M; Versteeg KS; Aalbers AGJ; Kok NFM; Buffart TE; Wiezer MJ; Boerma D; Los M; de Reuver PR; Bremers AJA; Verheul HMW; Kruijff S; de Groot DJA; Witkamp AJ; van Grevenstein WMU; Koopman M; Nederend J; Lahaye MJ; Kranenburg O; Fijneman RJA; van 't Erve I; Snaebjornsson P; Hemmer PHJ; Dijkgraaf MGW; Punt CJA; Tanis PJ; de Hingh IHJT;
JAMA Surg; 2021 Aug; 156(8):710-720. PubMed ID: 34009291
[TBL] [Abstract][Full Text] [Related]
7. Neoadjuvant and adjuvant therapy for resectable hepatocellular carcinoma: review of the randomised clinical trials.
Schwartz JD; Schwartz M; Mandeli J; Sung M
Lancet Oncol; 2002 Oct; 3(10):593-603. PubMed ID: 12372721
[TBL] [Abstract][Full Text] [Related]
8. Management of Intrahepatic Cholangiocarcinoma: A Narrative Review.
Tsung C; Quinn PL; Ejaz A
Cancers (Basel); 2024 Feb; 16(4):. PubMed ID: 38398130
[TBL] [Abstract][Full Text] [Related]
9. Adjuvant and Neoadjuvant Treatments for Resectable Hepatocellular Carcinoma.
Crook CJ; Li D
Curr Oncol Rep; 2023 Oct; 25(10):1191-1201. PubMed ID: 37688739
[TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant Checkpoint Immunotherapy and Melanoma: The Time Is Now.
Long GV; Menzies AM; Scolyer RA
J Clin Oncol; 2023 Jun; 41(17):3236-3248. PubMed ID: 37104746
[TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant and adjuvant treatment approaches for hepatocellular carcinoma: future outlook.
Sahin IH; Khalil L; Millett R; Kaseb A
Chin Clin Oncol; 2021 Feb; 10(1):7. PubMed ID: 33440948
[TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant Treatment in Patients With Resectable and Borderline Resectable Pancreatic Cancer.
Janssen QP; O'Reilly EM; van Eijck CHJ; Groot Koerkamp B
Front Oncol; 2020; 10():41. PubMed ID: 32083002
[TBL] [Abstract][Full Text] [Related]
13. Locoregional therapies for hepatocellular carcinoma: a critical review from the surgeon's perspective.
Poon RT; Fan ST; Tsang FH; Wong J
Ann Surg; 2002 Apr; 235(4):466-86. PubMed ID: 11923602
[TBL] [Abstract][Full Text] [Related]
14. Protocol of notable-HCC: a phase Ib study of neoadjuvant tislelizumab with stereotactic body radiotherapy in patients with resectable hepatocellular carcinoma.
Zhang B; Yue J; Shi X; Cui K; Li L; Zhang C; Sun P; Zhong J; Li Z; Zhao L
BMJ Open; 2022 Sep; 12(9):e060955. PubMed ID: 36115673
[TBL] [Abstract][Full Text] [Related]
15. Neoadjuvant Immunotherapy for Hepatocellular Carcinoma.
Marron TU; Schwartz M; Corbett V; Merad M
J Hepatocell Carcinoma; 2022; 9():571-581. PubMed ID: 35794901
[TBL] [Abstract][Full Text] [Related]
16. Lenvatinib combined with anti-PD-1 antibodies plus transcatheter arterial chemoembolization for neoadjuvant treatment of resectable hepatocellular carcinoma with high risk of recurrence: A multicenter retrospective study.
Wu JY; Wu JY; Li YN; Qiu FN; Zhou SQ; Yin ZY; Chen YF; Li B; Zhou JY; Yan ML
Front Oncol; 2022; 12():985380. PubMed ID: 36212494
[TBL] [Abstract][Full Text] [Related]
17. Chinese expert consensus on neoadjuvant and conversion therapies for hepatocellular carcinoma.
Zhao HT; Cai JQ
World J Gastroenterol; 2021 Dec; 27(47):8069-8080. PubMed ID: 35068855
[TBL] [Abstract][Full Text] [Related]
18. Adjuvant versus Neoadjuvant Immunotherapy for Hepatocellular Carcinoma: Clinical and Immunologic Perspectives.
Su YY; Li CC; Lin YJ; Hsu C
Semin Liver Dis; 2021 Aug; 41(3):263-276. PubMed ID: 34130338
[TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant Immunotherapy for NSCLC: Current Concepts and Future Approaches.
Uprety D; Mandrekar SJ; Wigle D; Roden AC; Adjei AA
J Thorac Oncol; 2020 Aug; 15(8):1281-1297. PubMed ID: 32522713
[TBL] [Abstract][Full Text] [Related]
20. Multidisciplinary treatment strategies in high-risk resectable melanoma: Role of adjuvant and neoadjuvant therapy.
McKean MA; Amaria RN
Cancer Treat Rev; 2018 Nov; 70():144-153. PubMed ID: 30195813
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
